Iqvia Holdings (IQV) Cost of Revenue (2012 - 2026)
Iqvia Holdings' (IQV) quarterly Cost of Revenue came in at $2.9 billion in Q2 2026, up 8.87% year-over-year from $2.7 billion in Q2 2025, and up 4.9% quarter-over-quarter from $2.8 billion in Q1 2026.
Analysis
Iqvia Holdings (IQV) Cost of Revenue (2012 - 2026) Analysis & Trends
Iqvia Holdings has disclosed Cost of Revenue across 15 years of filings, most recently posting $2.9 billion for Q2 2026.
- In Q2 2026, Cost of Revenue rose 8.87% year-over-year to $2.9 billion; the TTM figure through Jun 2026 stood at $11.4 billion (up 10.28% YoY), while the FY2025 annual figure was $10.9 billion, up 8.47% from the prior year.
- Cost of Revenue came in at $2.9 billion for Q2 2026 at Iqvia Holdings, up from $2.8 billion in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $2.9 billion in Q2 2026 to a low of $2.3 billion in Q3 2022.
- Average Cost of Revenue over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2023.
- Year-over-year, Cost of Revenue advanced 0.34% in 2022 and gained 13.49% in 2025.
- Over 5 years, Cost of Revenue stood at $2.4 billion in 2022, then gained by 2.95% to $2.5 billion in 2023, then grew by 4.12% to $2.6 billion in 2024, then increased by 13.49% to $2.9 billion in 2025, then climbed by 0.17% to $2.9 billion in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $2.9 billion in Q2 2026, $2.8 billion in Q1 2026, and $2.9 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | 2.93 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | 505.69 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | 1.58 Bn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | 552.01 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | 539.00 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 1.72 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 7.53 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 1.14 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.93 Bn |
| Mar 31, 2026 | 2.80 Bn |
| Dec 31, 2025 | 2.93 Bn |
| Sep 30, 2025 | 2.73 Bn |
| Jun 30, 2025 | 2.69 Bn |
| Mar 31, 2025 | 2.53 Bn |
| Dec 31, 2024 | 2.58 Bn |
| Sep 30, 2024 | 2.52 Bn |
| Jun 30, 2024 | 2.49 Bn |
| Mar 31, 2024 | 2.44 Bn |
| Dec 31, 2023 | 2.48 Bn |
| Sep 30, 2023 | 2.43 Bn |
| Jun 30, 2023 | 2.44 Bn |
| Mar 31, 2023 | 2.40 Bn |
| Dec 31, 2022 | 2.41 Bn |
| Sep 30, 2022 | 2.32 Bn |
| Jun 30, 2022 | 2.33 Bn |
| Mar 31, 2022 | 2.32 Bn |
| Dec 31, 2021 | 2.36 Bn |
| Sep 30, 2021 | 2.25 Bn |